Novo Nordisk, doctors offering samples of Levemir Type 2 diabetes treatment
PRINCETON, N.J. Novo Nordisk on Monday announced its Levemir Satisfaction Guarantee for U.S. patients taking Levemir (insulin detemir [rDNA origin] injection) to treat Type 2 diabetes.
First-time insulin users have the opportunity to ask their doctors about starting on Levemir (a basal insulin analog used to control hyperglycemia) and use it for up to three months. Patients who are satisfied with Levemir can mail in their reply card and receive a free pedometer to encourage healthy exercise habits. Patients who are not satisfied can return their reply card, along with their out-of-pocket receipts. After verification, these patients will receive a full refund of their out-of-pocket expenses and a free pedometer.“Insulin may be necessary to help patients with Type 2 diabetes control their blood sugar,” stated Camille Lee, vice president of marketing at Novo Nordisk. “As part of our commitment to these patients, Novo Nordisk wants to make the transition to insulin easy and convenient.”
As part of the Levemir Satisfaction Guarantee Program, Novo Nordisk has developed the Levemir tracking sheet to help physicians monitor their patient’s fasting plasma glucose average, their individual FPG goal, A1C level and weight.
FDA raises questions about efficacy of pain medication tamper-proofing
NEW YORK Questions have arisen as to whether a pill by Pain Therapeutics and King Pharmaceuticals is resistant to tampering.
A memo by the Food and Drug Administration Monday concerns the drug Remoxy, a formulation of oxycodone that uses liquid capsule drug-delivery technology designed to prevent misuse of the drug. Some people have abused oxycodone tablets by crushing them, dissolving it in water and then injecting it for its opiate-like effects.
The FDA’s memo said that Pain Therapeutics did not sufficiently conduct long-term tests of Remoxy to determine whether the oxycodone could be extracted and diverted, though Pain Therapeutics disputes that claim.
Titan releases earnings report for Q3 2008
SOUTH SAN FRANCISCO, Calif. Titan Pharmaceuticals has released financial results for third quarter 2008.
Total operating costs for the quarter, which ended Sept. 30, were $6 million, compared with $4.6 million for third quarter 2007, the company said. Net loss for the quarter was $5.9 million, compared to $4.3 million last year; losses in both cases totaled 10 cents a share. The increase in operating costs resulted mostly from an increase in research and development funding related to development of the opiate addiction treatment Probuphine (buprenorphine) and a slight increase in general and administrative costs.
“We have continued to streamline our expenses and focus our resources on the phase 3 clinical development of Probuphine,” Titan president and chief executive Marc Rubin said. “During the third quarter, we have engaged in discussions with several potential partners both in the U.S. and Europe, and we are continuing these efforts as we evaluate strategic alternatives for the company.”